Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases. Local targets link to admitted publications; unresolved targets remain external evidence.
The Gene Involved in X‐Linked Agammaglobulinaemia Is a Member of the Src Family of Protein‐Tyrosine Kinases
10.1038/361226a0 · 1993 · External reference
Regulation of B‐Cell Fate by Antigen‐Receptor Signals
10.1038/nri955 · 2002 · External reference
Role of Bruton's Tyrosine Kinase in B Cells and Malignancies
10.1186/s12943-018-0779-z · 2018 · External reference
Ibrutinib: Pediatric First Approval
10.1007/s40272-022-00543-w · 2023 · External reference
CAR T Cells and Time‐Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: The Phase 2 Tarmac Study
10.1182/blood.2023021306 · 2024 · External reference
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
10.1056/nejmoa2211582 · 2023 · External reference
BTK Inhibitor Resistance in B Cell Malignancies: Mechanisms and Potential Therapeutic Strategies
10.1016/j.blre.2025.101273 · 2025 · External reference
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Exerts Immunomodulatory Effects Through Regulation of Tumor‐Infiltrating Macrophages
10.18632/oncotarget.16836 · 2017 · External reference
Btk Inhibition Results in Impaired Cxcr4 Chemokine Receptor Surface Expression, Signaling and Function in Chronic Lymphocytic Leukemia
10.1038/leu.2015.316 · 2016 · External reference
Ibrutinib Modulates the Immunosuppressive CLL Microenvironment Through Stat3‐Mediated Suppression of Regulatory B‐Cell Function and Inhibition of the Pd‐1/Pd‐L1 Pathway
10.1038/leu.2017.304 · 2018 · External reference
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity
10.1615/critrevimmunol.2018025184 · 2018 · External reference
B Cell Signalling Pathways‐New Targets for Precision Medicine in Chronic Lymphocytic Leukaemia
10.1111/sji.12931 · 2020 · External reference
Targeting Bruton's Tyrosine Kinase in B Cell Malignancies
10.1038/nrc3702 · 2014 · External reference
Targeting Solid Tumors With BTK Inhibitors
10.3389/fcell.2021.650414 · 2021 · External reference
Bruton's Tyrosine Kinase Inhibitors: Recent Updates
10.3390/ijms25042208 · 2024 · External reference
Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X‐Linked Agammaglobulinemia
10.1016/0092-8674(93)90667-f · 1993 · External reference
Inhibitors Targeting Bruton's Tyrosine Kinase in Cancers: Drug Development Advances
10.1038/s41375-020-01072-6 · 2021 · External reference
Targeting Bruton's Tyrosine Kinase With Ibrutinib in B‐Cell Malignancies
10.1002/cpt.85 · 2015 · External reference
Structure‐Function Relationships of Covalent and Non‐Covalent BTK Inhibitors
10.3389/fimmu.2021.694853 · 2021 · External reference
Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but Not B‐Cell Receptor Signaling
10.1124/mol.116.107037 · 2017 · External reference
Does BTKi Improve CAR T‐Cell Therapy in MCL?
10.1182/blood.2023022898 · 2024 · External reference
New Means and Challenges in the Targeting of BTK
10.1158/1078-0432.ccr-23-0409 · 2024 · External reference
Pi3 Kinase Signals Bcr‐Dependent Mature B Cell Survival
10.1016/j.cell.2009.08.041 · 2009 · External reference
Targeting Bruton's Tyrosine Kinase (BTK) as a Signaling Pathway in Immune‐Mediated Diseases: From Molecular Mechanisms to Leading Treatments
10.1186/s42358-024-00401-y · 2024 · External reference
Phospholipase C‐Gamma2 and Vav Cooperate Within Signaling Microclusters to Propagate B Cell Spreading in Response to Membrane‐Bound Antigen
10.1084/jem.20072619 · 2008 · External reference
An Essential Role for Bruton's [Corrected] Tyrosine Kinase in the Regulation of B‐Cell Apoptosis
10.1073/pnas.93.20.10966 · 1996 · External reference
Ikappab Kinase Beta‐Induced Phosphorylation of Carma1 Contributes to Carma1 Bcl10 Malt1 Complex Formation in B Cells
10.1084/jem.20070379 · 2007 · External reference
In Vivo Ablation of Surface Immunoglobulin on Mature B Cells by Inducible Gene Targeting Results in Rapid Cell Death
10.1016/s0092-8674(00)80373-6 · 1997 · External reference
The Role of Bruton's Tyrosine Kinase in the Immune System and Disease
10.1111/imm.13416 · 2021 · External reference
Transphosphorylation of Bruton's Tyrosine Kinase on Tyrosine 551 Is Critical for B Cell Antigen Receptor Function
10.1074/jbc.272.25.15595 · 1997 · External reference
Administration of Il‐7 to Normal Mice Stimulates B‐Lymphopoiesis and Peripheral Lymphadenopathy
10.4049/jimmunol.147.2.561 · 1991 · External reference
Blnk Suppresses Pre‐B‐Cell Leukemogenesis Through Inhibition of Jak3
10.1182/blood-2008-07-166355 · 2009 · External reference
Constitutive Activation of Stat5a by Retrovirus Integration in Early Pre‐B Lymphomas of Sl/Kh Strain Mice
10.1073/pnas.112202899 · 2002 · External reference
Molecular Pathogenesis of Mantle Cell Lymphoma
10.1172/jci61272 · 2012 · External reference
Bruton Tyrosine Kinase Is Commonly Overexpressed in Mantle Cell Lymphoma and Its Attenuation by Ibrutinib Induces Apoptosis
10.1016/j.leukres.2013.07.028 · 2013 · External reference
Defective B Cell Development and Function in BTK‐Deficient Mice
10.1016/1074-7613(95)90114-0 · 1995 · External reference
Inactivation of BTK by Insertion of lacZ Reveals Defects in B Cell Development Only past the Pre‐B Cell Stage
10.1002/j.1460-2075.1996.tb00867.x · 1996 · External reference
Targeting the B Cell Receptor Pathway in Non‐Hodgkin Lymphoma
10.1080/13543784.2018.1482273 · 2018 · External reference
Selective Targeting of B Cells With Agonistic Anti‐Cd40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2‐Like B Cells and for the Suppression of Lupus in Mrl/Lpr Mice
10.4049/jimmunol.0803052 · 2009 · External reference
Toll‐Like Receptor Signalling
10.1038/nri1391 · 2004 · External reference
Toll‐Like Receptor Signaling in Cell Proliferation and Survival
10.1016/j.cyto.2009.08.010 · 2010 · External reference
Targeting B Cell Receptor Signalling in Cancer: Preclinical and Clinical Advances
10.1038/nrc.2017.121 · 2018 · External reference
Integration of B Cell Responses Through Toll‐Like Receptors and Antigen Receptors
10.1038/nri3190 · 2012 · External reference
Bruton's Tyrosine Kinase Is a Toll/Interleukin‐1 Receptor Domain‐Binding Protein That Participates in Nuclear Factor Kappa B Activation by Toll‐Like Receptor 4
10.1074/jbc.m301484200 · 2003 · External reference
MyD88 Adapter‐Like (Mal) Is Phosphorylated by Bruton's Tyrosine Kinase During Tlr2 and Tlr4 Signal Transduction
10.1074/jbc.m508892200 · 2006 · External reference
Toll‐Like Receptors: Lessons to Learn From Normal and Malignant Human B Cells
10.1182/blood-2008-02-140673 · 2008 · External reference
Toll‐Like Receptors in the Pathogenesis of Human B Cell Malignancies
10.1186/s13045-014-0057-5 · 2014 · External reference
Regulation of B‐Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B‐Cell Lymphomas
10.3390/cancers14040860 · 2022 · External reference
NF‐κB Signaling and Its Relevance to the Treatment of Mantle Cell Lymphoma
10.1186/s13045-018-0621-5 · 2018 · External reference
Toll‐Like Receptors Signaling: A Complex Network for NF‐κB Activation in B‐Cell Lymphoid Malignancies
10.1016/j.semcancer.2016.07.001 · 2016 · External reference
Tlr‐Activated B Cells Suppress T Cell‐Mediated Autoimmunity
10.4049/jimmunol.180.7.4763 · 2008 · External reference
Oncogenic Activation of NF‐Kappa B
10.1101/cshperspect.a000109 · 2010 · External reference
Phosphorylation of the Carma1 Linker Controls NF‐Kappa B Activation
10.1016/j.immuni.2005.09.014 · 2005 · External reference
Oncogenically Active Myd88 Mutations in Human Lymphoma
10.1038/nature09671 · 2011 · External reference
Bruton's Tyrosine Kinase and Phospholipase Cgamma2 Mediate Chemokine‐Controlled B Cell Migration and Homing
10.1016/j.immuni.2006.11.012 · 2007 · External reference
The Chemokine Receptor Cxcr4 in Cell Proliferation and Tissue Regeneration
10.3389/fimmu.2020.02109 · 2020 · External reference
Involvement of Cxcr4 in Normal and Abnormal Development
10.3390/cells8020185 · 2019 · External reference
G Protein Beta Gamma Subunits Act on the Catalytic Domain to Stimulate Bruton's Agammaglobulinemia Tyrosine Kinase
10.1074/jbc.m110390200 · 2002 · External reference
Binding of Beta Gamma Subunits of Heterotrimeric G Proteins to the PH Domain of Bruton Tyrosine Kinase
10.1073/pnas.91.23.11256 · 1994 · External reference
Specific Btk Inhibition Suppresses B Cell‐ and Myeloid Cell‐Mediated Arthritis
10.1038/nchembio.481 · 2011 · External reference
Fc‐gamma Receptors as Regulators of Immune Responses
10.1038/nri2206 · 2008 · External reference
Bruton's Tyrosine Kinase—a New Target for Immune Mediated Inflammatory Diseases?
10.1016/j.semarthrit.2025.152681 · 2025 · External reference
Mechanisms of Central Tolerance for B Cells
10.1038/nri.2017.19 · 2017 · External reference
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors Prn473 and Prn1008 (Rilzabrutinib)
10.1021/acs.jmedchem.1c01170 · 2022 · External reference
Bruton Tyrosine Kinase–Dependent Immune Cell Cross‐Talk Drives Pancreas Cancer
10.1158/2159-8290.cd-15-0827 · 2016 · External reference
Tyrosine Kinases BTK and Tec Regulate Osteoclast Differentiation by Linking RANK and ITAM Signals
10.1016/j.cell.2007.12.037 · 2008 · External reference
Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib Suppresses Osteoclastic Bone Resorption
10.1016/j.bonr.2019.100201 · 2019 · External reference
The Baff Receptor Transduces Survival Signals by Co‐Opting the B Cell Receptor Signaling Pathway
10.1016/j.immuni.2012.11.015 · 2013 · External reference
Baff Regulates B Cell Survival by Downregulating the Bh3‐Only Family Member Bim via the Erk Pathway
10.1084/jem.20051283 · 2005 · External reference
Baff: A Local and Systemic Target in Autoimmune Diseases
10.1111/j.1365-2249.2009.04007.x · 2009 · External reference
Excess Baff Rescues Self‐Reactive B Cells From Peripheral Deletion and Allows Them to Enter Forbidden Follicular and Marginal Zone Niches
10.1016/j.immuni.2004.05.010 · 2004 · External reference
Baff and Selection of Autoreactive B Cells
10.1016/j.it.2011.06.004 · 2011 · External reference
Normal Induction but Attenuated Progression of Germinal Center Responses in Baff and Baff‐R Signaling‐Deficient Mice
10.1084/jem.20030495 · 2003 · External reference
The Gene Involved in X‐Linked Agammaglobulinaemia Is a Member of the Src Family of Protein‐Tyrosine Kinases. 1993
10.1093/jimmunol/188.7.2948 · 2012 · External reference
BTK Inhibitors in Haematology: Beyond B Cell Malignancies
10.1016/j.tmrv.2022.06.009 · 2022 · External reference
BCR Targets Cyclin D2 via BTK and the P85α Subunit of Pi3‐K to Induce Cell Cycle Progression in Primary Mouse B Cells
10.1038/sj.onc.1206425 · 2003 · External reference
Chinese Expert Consensus on Bruton Tyrosine Kinase Inhibitors in the Treatment of B‐Cell Malignancies
10.1186/s40164-023-00448-5 · 2023 · External reference
Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase
10.1002/cmdc.200600221 · 2007 · External reference
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
10.1021/acschembio.6b00480 · 2016 · External reference
Bruton's Tyrosine Kinase Inhibitors With Distinct Binding Modes Reveal Differential Functional Impact on B‐Cell Receptor Signaling
10.1158/1535-7163.mct-22-0642 · 2024 · External reference
Bruton's Tyrosine Kinase Inhibitors (BTKis): Review of Preclinical Studies and Evaluation of Clinical Trials
10.3390/molecules28052400 · 2023 · External reference
Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option
10.3390/cancers13092198 · 2021 · External reference
BTK Inhibitors: Past, Present, and Future
10.1016/j.tips.2024.06.006 · 2024 · External reference
Progress in the Development of Small Molecular Inhibitors of the Bruton's Tyrosine Kinase (BTK) as a Promising Cancer Therapy
10.1016/j.bmc.2021.116358 · 2021 · External reference
Orelabrutinib: First Approval
10.1007/s40265-021-01482-5 · 2021 · External reference
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B‐Cell Non‐Hodgkin Lymphoma
10.1371/journal.pone.0159607 · 2016 · External reference
Discovery of Zanubrutinib (Bgb‐3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
10.1021/acs.jmedchem.9b00687 · 2019 · External reference
Preclinical Characterization of Pirtobrutinib, a Highly Selective, Noncovalent (Reversible) BTK Inhibitor
2023 · External reference
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors
10.1056/nejmoa2114110 · 2022 · External reference
Non‐Covalent BTK Inhibitors‐the New BTKids on the Block for B‐Cell Malignancies
10.3390/jpm11080764 · 2021 · External reference
Pirtobrutinib Inhibits Wild‐Type and Mutant Bruton's Tyrosine Kinase‐Mediated Signaling in Chronic Lymphocytic Leukemia
10.1038/s41408-022-00675-9 · 2022 · External reference
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
10.1056/nejmoa1400029 · 2014 · External reference
Are BTK and Plcg2 Mutations Necessary and Sufficient for Ibrutinib Resistance in Chronic Lymphocytic Leukemia?
10.1080/17474086.2018.1435268 · 2018 · External reference
Resistance Mutations to BTK Inhibitors Originate From the NF‐ΚB but Not From the Pi3k‐Ras‐Mapk Arm of the B Cell Receptor Signaling Pathway
10.3389/fimmu.2021.689472 · 2021 · External reference
Resistance to Bruton Tyrosine Kinase Inhibition in Chronic Lymphocytic Leukaemia and Non‐Hodgkin Lymphoma
10.1111/bjh.18418 · 2023 · External reference
Mutational Profile in Previously Treated Patients With Chronic Lymphocytic Leukemia Progression on Acalabrutinib or Ibrutinib
10.1182/blood.2023023659 · 2024 · External reference
Imbruvica (Ibrutinib), First‐in‐Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients With Relapsed Chronic Lymphocytic Leukemia
2015 · External reference
Ibrutinib (Imbruvica): A Novel Targeted Therapy for Chronic Lymphocytic Leukemia
2014 · External reference
Long‐Term Follow‐up of the Resonate Phase 3 Trial of Ibrutinib vs Ofatumumab
10.1182/blood-2018-08-870238 · 2019 · External reference
Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
10.1200/jco.21.01210 · 2021 · External reference
Detailed Safety Profile of Acalabrutinib vs Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia in the Elevate‐Rr Trial
10.1182/blood.2022018818 · 2023 · External reference
Acalabrutinib With or Without Obinutuzumab versus Chlorambucil and Obinutuzumab for Treatment‐Naive Chronic Lymphocytic Leukaemia (Elevate Tn): A Randomised, Controlled, Phase 3 Trial
10.1016/s0140-6736(20)30262-2 · 2020 · External reference
Targeted Drug Approvals in 2023: Breakthroughs by the FDA and NMPA
10.1038/s41392-024-01770-y · 2024 · External reference
Zanubrutinib versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III Aspen Study
10.1200/jco.22.02830 · 2023 · External reference
Safety and Efficacy of Zanubrutinib in Relapsed/Refractory Marginal Zone Lymphoma: Final Analysis of the Magnolia Study
10.1182/bloodadvances.2023010668 · 2023 · External reference
Novel Targeted Drugs Approved by the NMPA and FDA in 2019
10.1038/s41392-020-0164-4 · 2020 · External reference
Phase I/II Study of Tirabrutinib, a Second‐Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma
10.1093/neuonc/noaa145 · 2021 · External reference
A Phase 1 Clinical Trial of the Selective BTK Inhibitor Ono/Gs‐4059 in Relapsed and Refractory Mature B‐Cell Malignancies
10.1182/blood-2015-08-664086 · 2016 · External reference
Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi‐Center, Single‐Arm, Open‐Label, Phase 2 Study
10.1002/ajh.26826 · 2023 · External reference
Orelabrutinib versus Chemoimmunotherapy in Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Randomized, Phase 3 Trial
10.1038/s41392-026-02818-x · 2026 · External reference
Pirtobrutinib in Relapsed or Refractory B‐Cell Malignancies (Bruin): A Phase 1/2 Study
10.1016/s0140-6736(21)00224-5 · 2021 · External reference
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
10.1158/1078-0432.ccr-23-1272 · 2024 · External reference
Rilzabrutinib, an Oral Btk Inhibitor, in Immune Thrombocytopenia
10.1056/nejmoa2110297 · 2022 · External reference
Safety and Efficacy of Rilzabrutinib vs Placebo in Adults With Immune Thrombocytopenia: The Phase 3 Luna3 Study
10.1182/blood.2024027336 · 2025 · External reference
Remibrutinib in Chronic Spontaneous Urticaria
10.1056/nejmoa2408792 · 2025 · External reference
Dynamic Allostery Mediated by a Conserved Tryptophan in the Tec Family Kinases
10.1371/journal.pcbi.1004826 · 2016 · External reference
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
10.3390/cancers11121834 · 2019 · External reference
Btk Gatekeeper Residue Variation Combined With Cysteine 481 Substitution Causes Super‐Resistance to Irreversible Inhibitors Acalabrutinib, Ibrutinib and Zanubrutinib
10.1038/s41375-021-01123-6 · 2021 · External reference
Identification of a Structurally Novel BTK Mutation That Drives Ibrutinib Resistance in CLL
10.18632/oncotarget.11932 · 2016 · External reference
P110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
10.1158/1535-7163.mct-17-0784 · 2018 · External reference
Pharmacological and Genomic Profiling Identifies Nf‐Κb–Targeted Treatment Strategies for Mantle Cell Lymphoma
10.1038/nm.3435 · 2014 · External reference
Cotargeting of Btk and Malt1 Overcomes Resistance to Btk Inhibitors in Mantle Cell Lymphoma
10.1172/jci165694 · 2025 · External reference
Targeting B Cell Receptor Signaling With Ibrutinib in Diffuse Large B Cell Lymphoma
10.1038/nm.3884 · 2015 · External reference
Clonal Evolution in Patients With Chronic Lymphocytic Leukaemia Developing Resistance to BTK Inhibition
10.1038/ncomms11589 · 2016 · External reference
Genomic Evolution of Ibrutinib‐Resistant Clones in Waldenström Macroglobulinaemia
10.1111/bjh.16463 · 2020 · External reference
High‐Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations
10.1182/blood-2012-04-423517 · 2012 · External reference
Gain in the Short Arm of Chromosome 2 (2p+) Induces Gene Overexpression and Drug Resistance in Chronic Lymphocytic Leukemia: Analysis of the Central Role of Xpo1
10.1038/leu.2017.100 · 2017 · External reference
Acquired BTK Mutations Associated With Resistance to Noncovalent BTK Inhibitors
10.1182/bloodadvances.2022008955 · 2023 · External reference
Targeting Covalent and Non‐Covalent BTKi‐Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Lp‐168
10.1182/blood-2023-178259 · 2023 · External reference
Initial Results of a Phase 1 Dose Escalation Study of Lp‐168, a Novel Covalent and Non‐Covalent Next‐Generation Inhibitor of Bruton's Tyrosine Kinase
10.1182/blood-2023-186432 · 2023 · External reference
A Novel Dual Covalent and Non‐Covalent Next Generation Inhibitor of Bruton's Tyrosine Kinase Lp‐168 in Patients With Relapsed/Refractory B Cell Non‐Hodgkin Lymphoma: Safety and Efficacy Results From a Phase 1 Study
10.1182/blood-2023-180485 · 2023 · External reference
Rocbrutinib, a New‐Generation Btk Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Non‐GCB Diffuse Large B Cell Lymphoma
10.1182/blood-2024-194561 · 2024 · External reference
Preclinical Study of Dzd8586, a Non‐Covalent Lyn/Btk Dual Inhibitor With Excellent BBB Penetration, for the Treatment of B‐Cell Non‐Hodgkin Lymphoma (B‐NHL)
10.1182/blood-2023-185156 · 2023 · External reference
Phase 1/2 Studies of Dzd8586 in CLL/SLL Patients After Covalent or Non‐Covalent BTK Inhibitors and BTK Degraders
10.1200/jco.2025.43.16_suppl.7010 · 2025 · External reference
PROTAC‐Induced BTK Degradation as a Novel Therapy for Mutated Btk C481s Induced Ibrutinib‐Resistant B‐Cell Malignancies
10.1038/s41422-018-0055-1 · 2018 · External reference
Kinase‐Impaired BTK Mutations Are Susceptible to Clinical‐Stage BTK and Ikzf1/3 Degrader Nx‐2127
10.1126/science.adi5798 · 2024 · External reference
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader Nx‐5948 in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results From an Ongoing Phase 1a/B Study
10.1182/blood-2024-194839 · 2024 · External reference
Initial Findings From a First‐in‐Human Phase 1a/B Trial of Nx‐5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory B Cell Malignancies
10.1182/blood-2023-179508 · 2023 · External reference
First Results From a Phase 1, First‐in‐Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb‐16673 in Patients (Pts) With Relapsed or Refractory (R/R) B‐Cell Malignancies (Bgb‐16673‐101)
10.1182/blood-2023-180109 · 2023 · External reference
Abbv‐101, a Highly Potent and Selective Clinical Stage Bruton Tyrosine Kinase Degrader for the Treatment of B‐Cell Malignancies
10.1182/blood-2023-184835 · 2023 · External reference
Targeting BTK With Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
10.1056/nejmoa1215637 · 2013 · External reference
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
10.1056/nejmoa1400376 · 2014 · External reference
Ibrutinib Combined With Bendamustine and Rituximab Compared With Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (Helios): A Randomised, Double‐Blind, Phase 3 Study
10.1016/s1470-2045(15)00465-9 · 2016 · External reference
Ibrutinib‐Associated Atrial Fibrillation
2018 · External reference
Pirtobrutinib versus Ibrutinib in Treatment‐Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
10.1200/jco-25-02477 · 2026 · External reference
Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation
10.1182/blood.2019000840 · 2019 · External reference
Ibrutinib Plus Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma (Sympatico): A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled, Phase 3 Study
10.1016/s1470-2045(24)00682-x · 2025 · External reference
Partial Reconstitution of Humoral Immunity and Fewer Infections in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
10.1182/blood-2015-04-639203 · 2015 · External reference
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors
10.1007/s40257-020-00535-x · 2020 · External reference
Outcomes of CLL Patients Treated With Sequential Kinase Inhibitor Therapy: A Real World Experience
10.1182/blood-2016-05-716977 · 2016 · External reference
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients With Chronic Lymphocytic Leukemia
10.1634/theoncologist.2020-0388 · 2020 · External reference
Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound
10.1002/ajh.25023 · 2018 · External reference
Kinase Inhibitor Ibrutinib to Prevent Cytokine‐Release Syndrome After Anti‐CD19 Chimeric Antigen Receptor T Cells for B‐Cell Neoplasms
10.1038/leu.2016.262 · 2017 · External reference
Novel Strategies for the Mitigation of Cytokine Release Syndrome Induced by T Cell Engaging Therapies With a Focus on the Use of Kinase Inhibitors
10.1080/2162402x.2022.2083479 · 2022 · External reference
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B‐Cell and Immune Disorders
10.3390/biom16010123 · 2026 · External reference
Chronic Lymphocytic Leukemia: Disease Biology
10.1159/000533610 · 2024 · External reference
BTK Inhibitors in CLL: Second‐Generation Drugs and Beyond
10.1182/bloodadvances.2023012221 · 2024 · External reference
Bruton Tyrosine Kinase Inhibitors: Present and Future
10.1097/ppo.0000000000000412 · 2019 · External reference
B‐Cell Receptor Signaling as a Driver of Lymphoma Development and Evolution
10.1016/j.semcancer.2013.09.001 · 2013 · External reference
Acalabrutinib in Mantle Cell Lymphoma
10.1016/s0140-6736(17)33256-7 · 2018 · External reference
Durable Response With Single‐Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
10.1038/s41375-019-0575-9 · 2019 · External reference
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle‐Cell Lymphoma
10.1200/jco.23.00562 · 2023 · External reference
BTK Inhibitors in the Treatment of Hematological Malignancies and Inflammatory Diseases: Mechanisms and Clinical Studies
10.1186/s13045-022-01353-w · 2022 · External reference
Targeting Bruton Tyrosine Kinase With Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma
10.1182/blood-2016-10-747345 · 2017 · External reference
Ibrutinib in Previously Treated Waldenström's Macroglobulinemia
10.1056/nejmoa1501548 · 2015 · External reference
Long‐Term Follow‐Up of Ibrutinib Monotherapy in Treatment‐Naive Patients With Waldenstrom Macroglobulinemia
10.1038/s41375-021-01417-9 · 2022 · External reference
Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia
10.3324/haematol.2018.191999 · 2018 · External reference
A Randomized Phase 3 Trial of Zanubrutinib vs Ibrutinib in Symptomatic Waldenström Macroglobulinemia: The Aspen Study
10.1182/blood.2020006844 · 2020 · External reference
A Multicenter, Open‐Label, Phase II Study of Tirabrutinib (Ono/Gs‐4059) in Patients With Waldenström's Macroglobulinemia
10.1111/cas.14561 · 2020 · External reference
Single‐Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial
10.1182/blood-2017-09-804641 · 2018 · External reference
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non‐Germinal Center B‐Cell Diffuse Large B‐Cell Lymphoma
10.1200/jco.18.02403 · 2019 · External reference
Ibrutinib Monotherapy for Relapse or Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma: Final Analysis of the Phase II ‘Proof‐of‐Concept’ iLOC Study by the Lymphoma Study Association (LYSA) and the French Oculo‐Cerebral Lymphoma (LOC) Network
10.1016/j.ejca.2019.05.024 · 2019 · External reference
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
10.3390/neurolint14010009 · 2022 · External reference
A Systematic Review of Primary Central Nervous System Lymphoma
10.1007/s44178-024-00086-9 · 2024 · External reference
Managing Toxicities of Bruton Tyrosine Kinase Inhibitors
10.1182/hematology.2020000118 · 2020 · External reference
The Bruton Tyrosine Kinase Inhibitor Pci‐32765 Blocks B‐Cell Activation and Is Efficacious in Models of Autoimmune Disease and B‐Cell Malignancy
10.1073/pnas.1004594107 · 2010 · External reference
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects
10.3389/fcell.2021.630942 · 2021 · External reference
Final Analysis From Resonate: Up to Six Years of Follow‐up on Ibrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
10.1002/ajh.25638 · 2019 · External reference
Macrophages Eat Cancer Cells Using Their Own Calreticulin as a Guide: Roles of TLR and BTK
10.1073/pnas.1424907112 · 2015 · External reference
Ibrutinib Treatment Affects Collagen and Von Willebrand Factor‐Dependent Platelet Functions
10.1182/blood-2014-06-583294 · 2014 · External reference
High Incidence of Atrial Fibrillation in Patients Treated With Ibrutinib
10.1136/openhrt-2019-001049 · 2019 · External reference
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib
10.1016/j.cjca.2017.12.001 · 2018 · External reference
Biochemical Characterization of Tirabrutinib and Other Irreversible Inhibitors of Bruton's Tyrosine Kinase Reveals Differences in on—and Off—Target Inhibition
10.1016/j.bbagen.2020.129531 · 2020 · External reference
Ibrutinib for Chronic Graft‐Versus‐Host Disease After Failure of Prior Therapy: 1‐Year Update of a Phase 1b/2 Study
10.1016/j.bbmt.2019.06.023 · 2019 · External reference
Acalabrutinib (Acp‐196) in Relapsed Chronic Lymphocytic Leukemia
10.1056/nejmoa1509981 · 2016 · External reference
Toxicities and Outcomes of Acalabrutinib‐Treated Patients With Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
10.1182/blood-2019-130062 · 2019 · External reference
T Cells From CLL Patients Exhibit Features of T‐Cell Exhaustion but Retain Capacity for Cytokine Production
10.1182/blood-2012-09-457531 · 2013 · External reference
Ibrutinib Enhances Chimeric Antigen Receptor T‐Cell Engraftment and Efficacy in Leukemia
10.1182/blood-2015-11-679134 · 2016 · External reference
Antitumor Potency of an Anti‐Cd19 Chimeric Antigen Receptor T‐Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib
10.1097/cji.0000000000000307 · 2020 · External reference
BTK Inhibitors Improve Cart19 Cell Therapy by Modulating Immune System
10.1182/blood-2022-170898 · 2022 · External reference
Ibrutinib for Improved Chimeric Antigen Receptor T‐Cell Production for Chronic Lymphocytic Leukemia Patients
10.1002/ijc.33212 · 2021 · External reference
Tec Kinases Regulate T‐Lymphocyte Development and Function: New Insights Into the Roles of ITK and RLK/TXK
10.1111/j.1600-065x.2008.00757.x · 2009 · External reference
Ibrutinib Is an Irreversible Molecular Inhibitor of ITK Driving a Th1‐Selective Pressure in T Lymphocytes
10.1182/blood-2013-06-507947 · 2013 · External reference
Selective Expression Rather than Specific Function of TXK and ITK Regulate Th1 and Th2 Responses
10.4049/jimmunol.181.9.6125 · 2008 · External reference
Cutting Edge: ITK‐Dependent Signals Required for Cd4+ T Cells to Exert, but Not Gain, Th2 Effector Function
10.4049/jimmunol.176.7.3895 · 2006 · External reference
Structures of Human Bruton's Tyrosine Kinase in Active and Inactive Conformations Suggest a Mechanism of Activation for Tec Family Kinases
10.1002/pro.321 · 2010 · External reference
Ibrutinib Treatment Improves T Cell Number and Function in CLL Patients
10.1172/jci89756 · 2017 · External reference
Bruton Tyrosine Kinase Inhibitors Preserve Anti‐Cd19 Chimeric Antigen Receptor T‐Cell Functionality and Reprogram Tumor Micro‐Environment in B‐Cell Lymphoma
10.1016/j.jcyt.2023.03.005 · 2023 · External reference
Combining Ibrutinib and Checkpoint Blockade Improves Cd8+ T‐Cell Function and Control of Chronic Lymphocytic Leukemia in Em‐Tcl1 Mice
10.3324/haematol.2019.238154 · 2021 · External reference
Therapeutic Antitumor Immunity by Checkpoint Blockade Is Enhanced by Ibrutinib, an Inhibitor of both BTK and ITK
10.1073/pnas.1500712112 · 2015 · External reference
Cytotoxicity of the Cd3×Cd20 Bispecific Antibody Epcoritamab in CLL Is Increased by Concurrent BTK or Bcl‐2 Targeting
10.1182/bloodadvances.2022009517 · 2023 · External reference
B‐Cell Receptor‐Mediated Nfatc1 Activation Induces IL‐10/Stat3/Pd‐L1 Signaling in Diffuse Large B‐Cell Lymphoma
10.1182/blood-2018-03-841015 · 2018 · External reference
Pre‐Clinical Blocking of Pd‐L1 Molecule, which Expression Is Down Regulated by NF‐ΚB, Jak1/Jak2 and BTK Inhibitors, Induces Regression of Activated B‐Cell Lymphoma
10.1186/s12964-019-0391-x · 2019 · External reference
The Impacts of Zanubrutinib on Immune Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
10.1002/hon.2667 · 2019 · External reference
Myeloid‐Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor‐Bearing Hosts by Ibrutinib Treatment
10.1158/0008-5472.can-15-1490 · 2016 · External reference
Revving the Car—Combination Strategies to Enhance Car T Cell Effectiveness
10.1016/j.blre.2020.100695 · 2021 · External reference
Disruption of in Vivo Chronic Lymphocytic Leukemia Tumor‐Microenvironment Interactions by Ibrutinib–Findings From an Investigator‐Initiated Phase II Study
10.1158/1078-0432.ccr-15-1965 · 2016 · External reference
Evidence for Interaction of the Nlrp3 Inflammasome and Bruton's Tyrosine Kinase in Tumor‐Associated Macrophages: Implications for Myeloid Cell Production of Interleukin‐1beta
10.1080/2162402x.2019.1659704 · 2019 · External reference
The Pd‐1/Pd‐L1 Axis Contributes to Immune Metabolic Dysfunctions of Monocytes in Chronic Lymphocytic Leukemia
10.1038/leu.2016.214 · 2017 · External reference
Mechanisms of Pd‐L1/Pd‐1‐Mediated Cd8 T‐Cell Dysfunction in the Context of Aging‐Related Immune Defects in the Eμ‐Tcl1 CLL Mouse Model
10.1182/blood-2015-02-626754 · 2015 · External reference
Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells
10.1007/s10875-019-00632-5 · 2019 · External reference
Microenvironment Interactions and B‐Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Implications for Disease Pathogenesis and Treatment
10.1016/j.bbamcr.2015.07.009 · 2016 · External reference
Btk Inhibitor Combined With Anti‐Pd‐1 Monoclonal Antibody for the Treatment of CD20‐Negative Primary Central Nervous System Lymphoma: A Case Report
10.3892/ol.2022.13634 · 2023 · External reference
T‐Cell Expression of Bruton's Tyrosine Kinase Promotes Autoreactive T‐Cell Activation and Exacerbates Aplastic Anemia
10.1038/s41423-019-0270-9 · 2020 · External reference
Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy by the Non‐Covalent BTK Inhibitor Vecabrutinib
10.1182/blood-2021-151073 · 2021 · External reference
Human CAR T Cells With Cell‐Intrinsic Pd‐1 Checkpoint Blockade Resist Tumor‐Mediated Inhibition
10.1172/jci83092 · 2016 · External reference
Pd‐L1 Expression Is Characteristic of a Subset of Aggressive B‐Cell Lymphomas and Virus‐Associated Malignancies
10.1158/1078-0432.ccr-13-0855 · 2013 · External reference
Anti‐Pd‐1 Antibodies as a Salvage Therapy for Patients With Diffuse Large B Cell Lymphoma Who Progressed/Relapsed After Cart19/20 Therapy
10.1186/s13045-021-01120-3 · 2021 · External reference
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy Against CLL
10.3390/ijms21010068 · 2019 · External reference
Role of Pd‐1/Pd‐L1 Signaling Axis in Oncogenesis and Its Targeting by Bioactive Natural Compounds for Cancer Immunotherapy
10.1186/s40779-024-00586-9 · 2024 · External reference
The Role of Pd‐1/Pd‐L1 Axis in Treg Development and Function: Implications for Cancer Immunotherapy
10.2147/ott.s221340 · 2019 · External reference
Progranulin Induces Immune Escape in Breast Cancer via Up‐Regulating Pd‐L1 Expression on Tumor‐Associated Macrophages (TAMs) and Promoting CD8+ T Cell Exclusion
10.1186/s13046-020-01786-6 · 2021 · External reference
Evaluation of Cd160 and Cd200 Expression as Differentiating Markers Between Chronic Lymphocytic Leukemia and Other Mature B‐Cell Neoplasms
2020 · External reference
Cd157 and Cd200 at the Crossroads of Endothelial Remodeling and Immune Regulation
10.21037/sci.2019.04.01 · 2019 · External reference
Antibodies Selected From Combinatorial Libraries Block a Tumor Antigen That Plays a Key Role in Immunomodulation
10.1073/pnas.0510081103 · 2006 · External reference
Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B‐Cell Lymphomas (Transcend NHL 001): A Multicentre Seamless Design Study
10.1016/s0140-6736(20)31366-0 · 2020 · External reference
Interventions and Outcomes of Adult Patients With B‐All Progressing After Cd19 Chimeric Antigen Receptor T‐Cell Therapy
10.1182/blood.2020009515 · 2021 · External reference
Treatment Combining Cd200 Immune Checkpoint Inhibitor and Tumor‐Lysate Vaccination After Surgery for Pet Dogs With High‐Grade Glioma
10.3390/cancers11020137 · 2019 · External reference
CAR T Cell Combination Therapies to Treat Cancer
10.1016/j.ccell.2024.07.002 · 2024 · External reference
Phase 1/2 Study of Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results With >4 Years of Follow‐Up
10.1182/blood-2022-162394 · 2022 · External reference
Efficacy and Safety Analysis of the Zanubrutinib‐Based Bridging Regimen in Chimeric Antigen Receptor T‐Cell Therapy for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
2023 · External reference
Changes in Pd‐1 Expression on T Lymphocyte Subsets and Related Immune Indicators Before and After Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
10.1080/07853890.2024.2445190 · 2025 · External reference
Combination of Ibrutinib With Abt‐199: Synergistic Effects on Proliferation Inhibition and Apoptosis in Mantle Cell Lymphoma Cells Through Perturbation of Btk, Akt and Bcl2 Pathways
10.1111/bjh.13149 · 2015 · External reference
Anti‐Tumor Efficacy Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ono/Gs‐4059, in Combination With the Glycoengineered Type II Anti‐Cd20 Monoclonal Antibody Obinutuzumab (Ga101) Demonstrates Superior in Vivo Efficacy Compared to Ono/Gs‐4059 in Combination With Rituximab
10.1080/10428194.2016.1201567 · 2017 · External reference
Noncovalent Inhibition of C481s Bruton Tyrosine Kinase by Gdc‐0853: A New Treatment Strategy for Ibrutinib‐Resistant CLL
10.1182/blood-2017-10-809020 · 2018 · External reference
Addition of Btk Inhibitor Orelabrutinib to Rituximab Improved Anti‐Tumor Effects in B Cell Lymphoma
10.1016/j.omto.2021.03.015 · 2021 · External reference
Reshaping the Tumor Immune Microenvironment to Improve Car‐T Cell‐Based Cancer Immunotherapy
10.1186/s12943-024-02079-8 · 2024 · External reference
Myeloid‐Derived Suppressor Cells as a Therapeutic Target for Cancer
10.3390/cells9030561 · 2020 · External reference
Immunosuppression in Tumor Immune Microenvironment and Its Optimization From CAR T‐Cell Therapy
10.7150/thno.76854 · 2022 · External reference
Microenvironmental Regulation of Tumor Progression and Metastasis
10.1038/nm.3394 · 2013 · External reference
CAR T Cells Derived From Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the Tcl1 Chronic Lymphocytic Leukemia Model; Mice With CLL Treated With Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function Without Increasing the Cytokines of CRS
10.1182/blood-2019-125647 · 2019 · External reference
Concise Review: Emerging Principles From the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
10.1002/stem.2715 · 2018 · External reference
CAR‐T Cell Therapy: Current Limitations and Potential Strategies
10.1038/s41408-021-00459-7 · 2021 · External reference
Myeloid‐Derived Suppressor Cells in Cancer and Cancer Therapy
10.1038/s41571-023-00846-y · 2024 · External reference
Selectively Targeting Myeloid‐Derived Suppressor Cells Through Trail Receptor 2 to Enhance the Efficacy of CAR T Cell Therapy for Treatment of Breast Cancer
10.1136/jitc-2021-003237 · 2021 · External reference
Modulating Treg Stability to Improve Cancer Immunotherapy
10.1016/j.trecan.2023.07.015 · 2023 · External reference
Changes in T‐Cell Subpopulations and Cytokine Network During Early Period of Ibrutinib Therapy in Chronic Lymphocytic Leukemia Patients: The Significant Decrease in T Regulatory Cells Number
10.18632/oncotarget.16148 · 2017 · External reference
Macrophages and Cancer: From Mechanisms to Therapeutic Implications
10.1016/j.it.2015.02.004 · 2015 · External reference
Response‐Adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance Cd19 Car T‐Cell Therapy in Relapsed/Refractory Large B‐Cell Lymphoma: A Retrospective Observational Study
10.1002/ctm2.70310 · 2025 · External reference
Car‐T Treatment for Cancer: Prospects and Challenges
10.3389/fonc.2023.1288383 · 2023 · External reference
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
10.1016/j.cell.2015.08.016 · 2015 · External reference
Mtor‐ and Hif‐1α‐Mediated Aerobic Glycolysis as Metabolic Basis for Trained Immunity
10.1126/science.1250684 · 2014 · External reference
Advances in the Biology and Treatment of Waldenström's Macroglobulinemia: A Report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden
10.3816/clm.2009.n.001 · 2009 · External reference
The Bruton Tyrosine Kinase Inhibitor Pci‐32765 Thwarts Chronic Lymphocytic Leukemia Cell Survival and Tissue Homing in Vitro and in Vivo
10.1182/blood-2011-10-386417 · 2012 · External reference
Targeting the Immune Microenvironment in Mantle Cell Lymphoma: Implications for Current and Emerging Therapies
10.1080/10428194.2022.2086244 · 2022 · External reference
Critical Function of Bmx/Etk in Ischemia‐Mediated Arteriogenesis and Angiogenesis
2006 · External reference
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With Cd19‐Specific Chimeric Antigen Receptor‐Modified T Cells After Failure of Ibrutinib
10.1200/jco.2017.72.8519 · 2017 · External reference
Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
10.1084/jem.20040920 · 2004 · External reference
Egress of Cd19(+)Cd5(+) Cells Into Peripheral Blood Following Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Mantle Cell Lymphoma Patients
10.1182/blood-2013-02-482125 · 2013 · External reference
Idelalisib, a Selective Inhibitor of Phosphatidylinositol 3‐Kinase‐Δ, as Therapy for Previously Treated Indolent Non‐Hodgkin Lymphoma
10.1182/blood-2013-11-538546 · 2014 · External reference
The B Cell Antigen Receptor Controls Integrin Activity Through BTK and Plcgamma2
10.1084/jem.20011866 · 2003 · External reference
Combination of Pirtobrutinib and Lentiviral Transduced Bispecific Anti‐Cd20/Cd19 (Lv20.19) CAR T‐Cell Therapy to Improve Outcomes in Patients With Relapsed/Refractory Lymphoma
10.1200/jco.2024.42.16_suppl.7043 · 2024 · External reference
10.1182/blood-2024-209493
10.1182/blood-2024-209493 · External reference
Molecular Pathways: Targeting the Cxcr4–Cxcl12 Axis—Untapped Potential in the Tumor Microenvironment
10.1158/1078-0432.ccr-14-0914 · 2015 · External reference
Targeting Cxcl12 From Fap‐Expressing Carcinoma‐Associated Fibroblasts Synergizes With Anti‐Pd‐L1 Immunotherapy in Pancreatic Cancer
10.1073/pnas.1320318110 · 2013 · External reference
Cxcr4 Inhibition in Tumor Microenvironment Facilitates Anti‐Programmed Death Receptor‐1 Immunotherapy in Sorafenib‐Treated Hepatocellular Carcinoma in Mice
10.1002/hep.27665 · 2015 · External reference
Combination Therapy With BTK Inhibitor Plus Anti‐Pd‐1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL
10.1182/blood-2018-99-118773 · 2018 · External reference
Current Understanding and Management of CAR T Cell‐Associated Toxicities
10.1038/s41571-024-00903-0 · 2024 · External reference
CAR‐T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
10.3389/fimmu.2022.927153 · 2022 · External reference
Management of Chimeric Antigen Receptor T (CAR‐T) Cell‐Associated Toxicities
10.1007/s00134-024-07576-4 · 2024 · External reference
Cytokine Release Syndrome Associated With Chimeric‐Antigen Receptor T‐Cell Therapy: Clinicopathological Insights
10.1182/blood-2017-08-802413 · 2017 · External reference
Feasibility and Efficacy of CD19‐Targeted CAR T Cells With Concurrent Ibrutinib for CLL After Ibrutinib Failure
10.1182/blood.2019002936 · 2020 · External reference
Bruton Tyrosine Kinase Represents a Promising Therapeutic Target for Treatment of Chronic Lymphocytic Leukemia and Is Effectively Targeted by Pci‐32765
10.1182/blood-2011-01-328484 · 2011 · External reference
Ibrutinib Improves the Efficacy of Anti‐Cd19‐Car T‐Cell Therapy in Patients With Refractory Non‐Hodgkin Lymphoma
10.1111/cas.14915 · 2021 · External reference
Safety and Tolerability of Conditioning Chemotherapy Followed by CD19‐Targeted CAR T Cells for Relapsed/Refractory CLL
10.1172/jci.insight.122627 · 2019 · External reference
Anti‐Cd19 Car T Cells in Combination With Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
10.1182/bloodadvances.2022007317 · 2022 · External reference
Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte‐X19 Products
10.1182/blood-2021-146941 · 2021 · External reference
Efficacy and Safety of Chimeric Antigen Receptor T Cell Therapy Combined With Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B‐Cell Lymphoma
10.1097/cm9.0000000000003504 · 2025 · External reference
Pharmacological Profile and Clinical Outcomes of Kte‐X19 by Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the Zuma‐2 Trial
10.1182/blood-2020-136831 · 2020 · External reference
Management of Adverse Effects/Toxicity of Ibrutinib
10.1016/j.critrevonc.2019.02.001 · 2019 · External reference
BTK Inhibitors and CAR T‐Cell Therapy in Treating Mantle Cell Lymphoma‐Finding a Dancing Partner
10.1007/s11912-022-01286-0 · 2022 · External reference
Expert Consensus on the Management of B‐Cell Lymphoma‐Related Cardiovascular Diseases With Bruton Tyrosine Kinase Inhibitors (2023)
2023 · External reference
Ventricular Arrhythmias and Sudden Death in Patients Taking Ibrutinib
10.1182/blood-2016-10-742437 · 2017 · External reference
Efficacy and Safety‐Related Factors of BTK Inhibitors as a Bridge to Car‐T Therapy in R/R FL
10.1007/s00277-023-05255-w · 2023 · External reference
Gla/Drst Real‐World Outcome Analysis of CAR T‐Cell Therapies for Large B‐Cell Lymphoma in Germany
2022 · External reference
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
10.1158/2643-3230.bcd-21-0084 · 2021 · External reference
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
10.1056/nejmoa1407222 · 2014 · External reference
Long‐Term Outcomes Following CAR T Cell Therapy: What We Know So Far
10.1038/s41571-023-00754-1 · 2023 · External reference
The Basic Principles of Chimeric Antigen Receptor Design
10.1158/2159-8290.cd-12-0548 · 2013 · External reference
Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience From the US Lymphoma CAR T Consortium
10.1182/blood-2021-147563 · 2021 · External reference
Analysis of Outcomes and Predictors of Response in Patients With Relapsed Mantle Cell Lymphoma Treated With Brexucabtagene Autoleucel
10.1182/blood-2021-153277 · 2021 · External reference
Efficacy and Safety of Zanubrutinib Combined With Chimeric Antigen Receptor T‐Cell Therapy Targeting Cd19 in Refractory or Relapsed Diffuse Large B Cell Lymphoma: A Retrospective Analysis
10.1016/j.ctarc.2025.100902 · 2025 · External reference
Predictors and Responses to Varying Durations of BTK Inhibitor Bridging Therapy Before Anti‐CD19 CAR‐T Cell Therapy in Patients With Relapsed/Refractory DLBCL
2026 · External reference
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma
10.3390/cancers15051437 · 2023 · External reference
Safety and Activity of Ibrutinib in Combination With Nivolumab in Patients With Relapsed Non‐Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia: A Phase 1/2a Study
10.1016/s2352-3026(18)30217-5 · 2019 · External reference
Safety and Activity of Ibrutinib in Combination With Durvalumab in Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B‐Cell Lymphoma
10.1002/ajh.25659 · 2020 · External reference
An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination With PD‐1 Inhibitor Tislelizumab in Patients With Previously Treated B‐Cell Lymphoid Malignancies
10.1182/blood-2019-125485 · 2019 · External reference
Biology and Treatment of Richter Syndrome
10.1182/blood-2018-01-791376 · 2018 · External reference
Richter Transformation in Chronic Lymphocytic Leukemia (CLL)‐a Pooled Analysis of German CLL Study Group (GCLLSG) Front Line Treatment Trials
10.1038/s41375-020-0797-x · 2021 · External reference
Acalabrutinib Monotherapy for Treatment of Chronic Lymphocytic Leukaemia (Ace‐Cl‐001): Analysis of the Richter Transformation Cohort of an Open‐Label, Single‐Arm, Phase 1–2 Study
10.1016/s2352-3026(21)00305-7 · 2021 · External reference
Richter Transformation in the Era of Novel Agents
10.1182/asheducation-2018.1.256 · 2018 · External reference
Tislelizumab plus Zanubrutinib for Richter Transformation: The Phase 2 Rt1 Trial
10.1038/s41591-023-02722-9 · 2024 · External reference
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
10.1016/j.ccell.2017.04.012 · 2017 · External reference
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
10.1158/2159-8290.cd-17-0613 · 2017 · External reference
Pd‐1 Blockade With Nivolumab in Relapsed/Refractory Primary Central Nervous System and Testicular Lymphoma
10.1182/blood-2017-01-764209 · 2017 · External reference
S224: Preliminary Results of a Phase II Study of Orelabrutinib in Combination With Anti‐Pd‐1 Monoclonal Antibody in Refractory or Relapsed Primary CNS Lymphoma
10.1097/01.hs9.0000843788.10370.07 · 2022 · External reference
BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti‐CD20 Antibody Therapy Surpasses Cit (Chemoimmunotherapy)in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta‑Analysis of Randomized Controlled Trials
10.1182/blood-2025-7426 · 2025 · External reference
Ibrutinib plus Obinutuzumab versus Chlorambucil Plus Obinutuzumab in First‐Line Treatment of Chronic Lymphocytic Leukaemia (Illuminate): A Multicentre, Randomised, Open‐Label, Phase 3 Trial
10.1016/s1470-2045(18)30788-5 · 2019 · External reference
Acalabrutinib With or Without Obinutuzumab versus Chlorambucil and Obinutuzumab for Treatment‐Naive Chronic Lymphocytic Leukaemia (Elevate‐Tn): A Randomised, Controlled, Phase 3 Trial
10.1016/s0140-6736(20)30262-2 · 2020 · External reference
Ublituximab (Tg‐1101), a Novel Glycoengineered Anti‐Cd20 Antibody, in Combination With Ibrutinib Is Safe and Highly Active in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukaemia: Results of a Phase 2 Trial
10.1111/bjh.14447 · 2017 · External reference
Safety and Activity of BTK Inhibitor Ibrutinib Combined With Ofatumumab in Chronic Lymphocytic Leukemia: A Phase 1b/2 Study
10.1182/blood-2014-12-617522 · 2015 · External reference
Ibrutinib plus Rituximab vs Ibrutinib Monotherapy in Patients With Waldenström Macroglobulinemia: A Pooled Analysis
10.1182/bloodadvances.2025016536 · 2025 · External reference
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients With Untreated CLL
10.1056/nejmoa1812836 · 2018 · External reference
First‐Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
10.1056/nejmoa2213093 · 2023 · External reference
Combined Pirtobrutinib, Venetoclax, and Obinutuzumab as First‐Line Treatment of Patients With Chronic Lymphocytic Leukemia (CLL)
10.1182/blood-2024-211454 · 2024 · External reference
Ibrutinib‐Based Therapy Reinvigorates Cd8+ T Cells Compared to Chemoimmunotherapy: Immune Monitoring From the E1912 Trial
10.1182/blood.2023020554 · 2024 · External reference
Combining BTK Inhibitors With Bcl2 Inhibitors for Treating Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
10.1186/s40364-022-00357-5 · 2022 · External reference
Synergistic Disruption of BTK and Bcl‐2 Causes Apoptosis While Inducing Ferroptosis in Double‐Hit Lymphoma
10.1016/j.ejphar.2023.175526 · 2023 · External reference
Combined Ibrutinib and Venetoclax Treatment vs Single Agents in the Tcl1 Mouse Model of Chronic Lymphocytic Leukemia
10.1182/bloodadvances.2021004861 · 2021 · External reference
Pharmacological and Protein Profiling Suggests Venetoclax (Abt‐199) as Optimal Partner With Ibrutinib in Chronic Lymphocytic Leukemia
10.1158/1078-0432.ccr-14-2809 · 2015 · External reference
Bruton's Tyrosine Kinase Inhibition Increases Bcl‐2 Dependence and Enhances Sensitivity to Venetoclax in Chronic Lymphocytic Leukemia
10.1038/leu.2017.32 · 2017 · External reference
Ibrutinib and Venetoclax Target Distinct Subpopulations of CLL Cells: Implication for Residual Disease Eradication
10.1038/s41408-021-00429-z · 2021 · External reference
Combination of Ibrutinib and Abt‐199 in Diffuse Large B‐Cell Lymphoma and Follicular Lymphoma
10.1158/1535-7163.mct-16-0555 · 2017 · External reference
Ibrutinib plus Venetoclax for First‐Line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial
10.1001/jamaoncol.2021.1649 · 2021 · External reference
Ibrutinib (Ibr) plus Venetoclax (Ven) for First‐Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1‐Year Disease‐Free Survival (DFS) Results From the MRD Cohort of the Phase 2 Captivate Study
10.1182/blood-2020-134446 · 2020 · External reference
Fixed‐Duration Ibrutinib‐Venetoclax in Patients With Chronic Lymphocytic Leukemia and Comorbidities
10.1056/evidoa2200006 · 2022 · External reference
Ibrutinib plus Venetoclax for the Treatment of Mantle‐Cell Lymphoma
10.1056/nejmoa1715519 · 2018 · External reference
The Role of B Cells in the Pathogenesis of Graft‐Versus‐Host Disease
10.1182/blood-2008-10-161638 · 2009 · External reference
Ibrutinib for Bridging to Allogeneic Hematopoietic Cell Transplantation in Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Study by the EBMT Chronic Malignancies and Lymphoma Working Parties
10.1038/s41409-018-0207-4 · 2019 · External reference
Ibrutinib Efficacy and Tolerability in Patients With Relapsed Chronic Lymphocytic Leukemia Following Allogeneic Hct
10.1182/blood-2016-06-715284 · 2016 · External reference
Inhibition of BTK and ITK With Ibrutinib Is Effective in the Prevention of Chronic Graft‐Versus‐Host Disease in Mice
10.1371/journal.pone.0137641 · 2015 · External reference
Ibrutinib Treatment Ameliorates Murine Chronic Graft‐Versus‐Host Disease
10.1172/jci75328 · 2014 · External reference
Ibrutinib for Chronic Graft‐Versus‐Host Disease After Failure of Prior Therapy
10.1182/blood-2017-07-793786 · 2017 · External reference
The Down‐Regulation of Il1alpha and Il6, in Monocytes Exposed to Extracorporeal Photopheresis (ECP)‐Treated Lymphocytes, Is Not Dependent on Lymphocyte Phosphatidylserine Externalization
10.1111/j.1432-2277.2006.00278.x · 2006 · External reference
A Novel Isoform of the B Cell Tyrosine Kinase Btk Protects Breast Cancer Cells From Apoptosis
10.1002/gcc.22091 · 2013 · External reference
P65btk Is a Novel Potential Actionable Target in KRAS‐Mutated/EGFR‐Wild Type Lung Adenocarcinoma
10.1186/s13046-019-1199-7 · 2019 · External reference
Bmx‐Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer
10.1158/0008-5472.can-17-3615 · 2018 · External reference
Bruton Tyrosine Kinase‐Dependent Immune Cell Cross‐Talk Drives Pancreas Cancer
10.1158/2159-8290.cd-15-0827 · 2016 · External reference
P65btk Is a Novel Biomarker and Therapeutic Target in Solid Tumors
10.3389/fcell.2021.690365 · 2021 · External reference
A Novel Oncogenic BTK Isoform Is Overexpressed in Colon Cancers and Required for Ras‐Mediated Transformation
10.1038/onc.2015.504 · 2016 · External reference
Targeting BTK/ETK of Prostate Cancer Cells by a Novel Dual Inhibitor
10.1038/cddis.2014.343 · 2014 · External reference
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
10.3390/cells11081338 · 2022 · External reference
Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib Suppresses Stem‐Like Traits in Ovarian Cancer
10.18632/oncotarget.3658 · 2015 · External reference
Extraordinary Clinical Response to Ibrutinib in Low‐Grade Ovarian Cancer Guided by Organoid Drug Testing
10.1038/s41698-023-00379-8 · 2023 · External reference
Ibrutinib as a Potential Therapeutic Option for HER2 Overexpressing Breast Cancer—the Role of Stat3 and P21
10.1007/s10637-019-00837-w · 2020 · External reference
Ibrutinib Treatment Inhibits Breast Cancer Progression and Metastasis by Inducing Conversion of Myeloid‐Derived Suppressor Cells to Dendritic Cells
10.1038/s41416-020-0743-8 · 2020 · External reference
Combination of FTO and BTK Inhibitors Synergistically Suppresses the Malignancy of Breast Cancer Cells
10.7150/ijbs.117999 · 2025 · External reference
Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
10.1158/0008-5472.can-14-2852 · 2015 · External reference
The Effect of Ibrutinib on Radiosensitivity in Pancreatic Cancer Cells by Targeting EGFR/AKT/mTOR Signaling Pathway
10.1016/j.biopha.2020.110133 · 2020 · External reference
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer
10.3390/cancers11060880 · 2019 · External reference
Btk Inhibitors Synergise With 5‐Fu to Treat Drug‐Resistant Tp53‐Null Colon Cancers
10.1002/path.5347 · 2020 · External reference
Btk Isoforms P80 and P65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression
10.3390/cancers15010310 · 2023 · External reference
High Expression of Bruton's Tyrosine Kinase (BTK) Is Required for EGFR‐Induced NF‐κB Activation and Predicts Poor Prognosis in Human Glioma
10.1186/s13046-017-0600-7 · 2017 · External reference
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the Pd‐L1 Inhibitor Durvalumab in Patients With Pretreated Solid Tumors
10.1159/000500571 · 2019 · External reference
Ibrutinib in Combination With Nab‐Paclitaxel and Gemcitabine for First‐Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma: Phase III Resolve Study
10.1016/j.annonc.2021.01.070 · 2021 · External reference
A Phase 1/2 Trial of Ibrutinib in Combination With Pembrolizumab in Patients With Mismatch Repair Proficient Metastatic Colorectal Cancer
10.1038/s41416-021-01368-z · 2021 · External reference
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
10.4049/jimmunol.167.8.4710 · 2001 · External reference
Microbiota‐Induced Tertiary Lymphoid Tissues Aggravate Inflammatory Disease in the Absence of RORγt and LTI Cells
10.1084/jem.20100052 · 2011 · External reference
Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
10.1007/s40265-021-01592-0 · 2021 · External reference
Emerging Therapies in Immune Thrombocytopenia
10.3390/jcm10051004 · 2021 · External reference
FcγRI and FcγRIII on Splenic Macrophages Mediate Phagocytosis of Anti‐Glycoprotein IIb/IIIa Autoantibody‐Opsonized Platelets in Immune Thrombocytopenia
10.3324/haematol.2020.248385 · 2021 · External reference
Desialylation Is a Mechanism of Fc‐Independent Platelet Clearance and a Therapeutic Target in Immune Thrombocytopenia
10.1038/ncomms8737 · 2015 · External reference
Incidence and Description of Autoimmune Cytopenias During Treatment With Ibrutinib for Chronic Lymphocytic Leukemia
10.1038/leu.2015.273 · 2016 · External reference
Effects of Orelabrutinib, a BTK Inhibitor, on Antibody‐Mediated Platelet Destruction in Primary Immune Thrombocytopenia
10.1111/bjh.20045 · 2025 · External reference
Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Modulates Fc Gamma Receptors to Inhibit Platelet Destruction for Alleviation of Refractory Immune Thrombocytopenia
10.1080/16078454.2025.2545078 · 2025 · External reference
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Zanubrutinib in Immune Thrombocytopenia
10.1002/ajh.27718 · 2025 · External reference
Btk Inhibition Ameliorates Kidney Disease in Spontaneous Lupus Nephritis
10.1016/j.clim.2018.10.008 · 2018 · External reference
Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus
10.3389/fimmu.2017.01986 · 2017 · External reference
Highly Selective Inhibition of Bruton's Tyrosine Kinase Attenuates Skin and Brain Disease in Murine Lupus
10.1186/s13075-017-1500-0 · 2018 · External reference
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (Btk) Inhibitor for the Treatment of Immunological Diseases
10.1021/acs.jmedchem.9b00794 · 2019 · External reference
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models
10.4049/jimmunol.1800583 · 2019 · External reference
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (Gdc‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
10.1002/art.41811 · 2021 · External reference
Lb0005 Orelabrutinib, an Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), for the Treatment of Systemic Lupus Erythematosus (SLE): Results of a Randomized, Double‐Blind, Placebo‐Controlled, Phase Ib/IIa Dose‐Finding Study
10.1136/annrheumdis-2022-eular.5086a · 2022 · External reference
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
10.1002/art.42926 · 2024 · External reference
Genes on the X Chromosome Affect Development of Collagen‐Induced Arthritis in Mice
10.1111/j.1365-2249.1993.tb08218.x · 1993 · External reference
Hm71224, a Novel Bruton's Tyrosine Kinase Inhibitor, Suppresses B Cell and Monocyte Activation and Ameliorates Arthritis in a Mouse Model: A Potential Drug for Rheumatoid Arthritis
10.1186/s13075-016-0988-z · 2016 · External reference
Discovery of Branebrutinib (Bms‐986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
10.1021/acs.jmedchem.9b00167 · 2019 · External reference
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial (Andes Study)
10.1002/art.41275 · 2020 · External reference
Spebrutinib (Cc‐292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients With Rheumatoid Arthritis: Results From a Mechanistic Study
10.1007/s40744-019-00182-7 · 2020 · External reference
A Novel Tricyclic Btk Inhibitor Suppresses B Cell Responses and Osteoclastic Bone Erosion in Rheumatoid Arthritis
10.1038/s41401-020-00578-0 · 2021 · External reference
Characterisation of the Safety Profile of Evobrutinib in Over 1000 Patients From Phase II Clinical Trials in Multiple Sclerosis, Rheumatoid Arthritis and Systemic Lupus Erythematosus: An Integrated Safety Analysis
10.1136/jnnp-2022-328799 · 2023 · External reference
Bruton's Tyrosine Kinase Inhibitor Bms‐986142 in Experimental Models of Rheumatoid Arthritis Enhances Efficacy of Agents Representing Clinical Standard‐of‐Care
10.1371/journal.pone.0181782 · 2017 · External reference
Evaluation of Bms‐986142, a Reversible Bruton's Tyrosine Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis: A Phase 2, Randomised, Double‐Blind, Dose‐Ranging, Placebo‐Controlled, Adaptive Design Study
10.1016/s2665-9913(23)00089-9 · 2023 · External reference
Discovery and Preclinical Characterization of Biib091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
10.1021/acs.jmedchem.1c00926 · 2022 · External reference
Inhibition of Bruton's Tyrosine Kinase Selectively Prevents Antigen‐Activation of B Cells and Ameliorates B Cell‐Mediated Experimental Autoimmune Encephalomyelitis
2018 · External reference
Unresolved reference
External reference
Recent Advances in Understanding Pathogenesis and Therapeutic Strategies of Systemic Lupus Erythematosus
10.1016/j.intimp.2020.107028 · 2020 · External reference
BTK Inhibition Limits B‐Cell‐T‐Cell Interaction Through Modulation of B‐Cell Metabolism: Implications for Multiple Sclerosis Therapy
10.1007/s00401-022-02411-w · 2022 · External reference
Safety and Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (FENopta): A Multicentre, Double‐Blind, Randomised, Placebo‐Controlled, Phase 2 Trial and Open‐Label Extension Study
10.1016/s1474-4422(25)00174-7 · 2025 · External reference
BTK Blockers Make Headway in Multiple Sclerosis
10.1038/s41587-020-00790-7 · 2021 · External reference
Placebo‐Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis
10.1056/nejmoa1901981 · 2019 · External reference
Mechanisms and New Strategies for Primary Sjögren's Syndrome
10.1146/annurev-med-043015-123313 · 2017 · External reference
Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Sjögren's Syndrome: A Randomized, Phase 2, Double‐Blind, Placebo‐Controlled Study
10.1093/rheumatology/keac167 · 2022 · External reference
Fenebrutinib in H(1) Antihistamine‐Refractory Chronic Spontaneous Urticaria: A Randomized Phase 2 Trial
10.1038/s41591-021-01537-w · 2021 · External reference
Rilzabrutinib in Antihistamine‐Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial
10.1001/jamadermatol.2025.0733 · 2025 · External reference
Short‐Term Ibrutinib Therapy Suppresses Skin Test Responses and Eliminates IgE‐Mediated Basophil Activation in Adults With Peanut or Tree Nut Allergy
10.1016/j.jaci.2017.12.987 · 2018 · External reference
Remibrutinib (Lou064): A Selective Potent Oral Btk Inhibitor With Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial
10.1111/cts.13005 · 2021 · External reference
The Immunomodulatory Mechanisms of BTK Inhibition in CLL and beyond
10.3390/cancers16213574 · 2024 · External reference
348 Differently Specific Btk Inhibitors Impair Anti‐Tumor T‐Cell Immunity
2024 · External reference
Cd8 T Cell Exhaustion During Chronic Viral Infection and Cancer
10.1146/annurev-immunol-041015-055318 · 2019 · External reference
Btk Is the Target That Keeps on Giving: A Review of Btk‐Degrader Drug Development, Clinical Data, and Future Directions in CLL
10.3390/cancers17030557 · 2025 · External reference
A First‐in‐Human Phase 1 Trial of Nx‐2127, a First‐in‐Class Bruton's Tyrosine Kinase (BTK) Dual‐Targeted Protein Degrader With Immunomodulatory Activity, in Patients With Relapsed/Refractory B Cell Malignancies
10.1182/blood-2023-179872 · 2023 · External reference
Mutation in Bruton Tyrosine Kinase (BTK) A428d Confers Resistance to BTK‐Degrader Therapy in Chronic Lymphocytic Leukemia
10.1038/s41375-024-02317-4 · 2024 · External reference
Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia: Current Status and Perspectives for Clinical and Diagnostic Practice
10.1038/s41375-025-02662-y · 2025 · External reference
